Immuneering (IMRX) Gross Margin (2020 - 2022)
Historic Gross Margin for Immuneering (IMRX) over the last 3 years, with Q4 2022 value amounting to 100.0%.
- Immuneering's Gross Margin rose 1087700.0% to 100.0% in Q4 2022 from the same period last year, while for Sep 2023 it was 100.0%, marking a year-over-year increase of 719900.0%. This contributed to the annual value of 50.11% for FY2022, which is 55500.0% up from last year.
- According to the latest figures from Q4 2022, Immuneering's Gross Margin is 100.0%, which was up 1087700.0% from 49.6% recorded in Q3 2022.
- Immuneering's Gross Margin's 5-year high stood at 100.0% during Q4 2022, with a 5-year trough of 8.77% in Q4 2021.
- In the last 3 years, Immuneering's Gross Margin had a median value of 50.55% in 2022 and averaged 47.78%.
- Its Gross Margin has fluctuated over the past 5 years, first crashed by -376200bps in 2021, then surged by 1087700bps in 2022.
- Quarter analysis of 3 years shows Immuneering's Gross Margin stood at 28.85% in 2020, then tumbled by -130bps to 8.77% in 2021, then soared by 1240bps to 100.0% in 2022.
- Its Gross Margin was 100.0% in Q4 2022, compared to 49.6% in Q3 2022 and 49.23% in Q2 2022.